Cargando…
Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic
SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike protein have entered clinical trials with three (REGN-COV2, LY3819253/LY-CoV555, and VIR-7831/VIR-7832) in phase 3. On 9 Novem...
Autores principales: | Sun, Yaping, Ho, Mitchell |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717131/ https://www.ncbi.nlm.nih.gov/pubmed/33912795 http://dx.doi.org/10.1093/abt/tbaa025 |
Ejemplares similares
-
Perspectives on the development of neutralizing antibodies against SARS-CoV-2
por: Ho, Mitchell
Publicado: (2020) -
Battle against the pandemic: Emergence of SARS-CoV2 variants and global challenge
por: Kumar, Saurabh, et al.
Publicado: (2021) -
Current status of therapeutic monoclonal antibodies against SARS-CoV-2
por: Kumar, Sanjeev, et al.
Publicado: (2021) -
Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
por: Shrestha, Lok Bahadur, et al.
Publicado: (2021) -
Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19
por: Gómez, Carmen Elena, et al.
Publicado: (2021)